89 bioThis phase2b NASH company is currently valued $350M versus THTX's $310M, they only have one program and that's it. I believe the company still needs to go out there and promote their programs including NASH whether they are currently negotiating a partnership or not. Investors need to be educated in order to factor in the value of their now finalized NASH protocol. We have few months before the oncology results will be announced, this is a perfect timing to fill the gap between news by starting the NASH marketing. There is no reason why not now that their negotiations are finalized.
ETNB $16.97 (-0.47%) on Yahoo Finance
https://finance.yahoo.com/quote/ETNB?p=ETNB